Copper Inhibitors
1 drugsAbout Copper
Copper is an essential trace element involved in various biological processes. It plays a crucial role in cellular functions, making it a potential target for therapeutic intervention. Its modulation can be achieved through various drug modalities.
Currently, there is no genetic evidence available linking copper directly to specific diseases. Further research is needed to understand copper's role in disease pathogenesis and identify potential patient populations.
There is one FDA-approved drug, CUVRIOR, a small molecule, targeting copper. CUVRIOR, developed by ORPHALAN, is approved for a therapeutic area classified as "Other".
Top Copper Drugs
ORPHALAN is the only company with an approved drug targeting copper.
Low competition represents an opportunity for new entrants in this space.
Copper Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Copper, using small molecule modality.
Exploring other modalities like antibodies or peptides could offer differentiation.
Copper Clinical Trials 2 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Copper. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Copper Drug Approval Timeline (2022 - 2022)
The first and most recent drug approval for copper was CUVRIOR in 2022.
Recent approval suggests renewed interest, but saturation is not a concern yet.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Copper. A trial counts if an approved drug acting on Copper is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.